Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 9/20 | 0.84 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.40 |
| ▸ | WNT1 | P04628 | 2/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CLK3 | P49761 | 1/20 | 0.38 |
| ▸ | COMT | P21964 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063925 | 0.92 | CALCA (0.84) | CALCA | |
| SCHEMBL6046599 | 0.91 | CALCA (1.00) | CALCAEGLN1DYRK1AWNT1CLK2 | |
| SCHEMBL4060939 | 0.90 | CALCA (0.79) | CALCA | |
| SCHEMBL7263617 | 0.88 | CALCA (0.67) | CALCA | |
| SCHEMBL7262555 | 0.86 | CALCA (0.65) | CALCAEGLN1COMT | |
| SCHEMBL4763683 | 0.86 | CALCA (0.64) | CALCACOMT | |
| SCHEMBL4765294 | 0.86 | CALCA (0.64) | CALCA | |
| SCHEMBL4767331 | 0.85 | CALCA (0.63) | CALCACOMT | |
| SCHEMBL4766074 | 0.85 | CALCA (0.63) | CALCACOMT | |
| SCHEMBL4765622 | 0.85 | CALCA (0.63) | CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173046-A1 | Hydroxypyridine cgrp receptor antagonists | MERCK SHARP & DOHME CORP. | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173046-A1 | Hydroxypyridine cgrp receptor antagonists | HRH4, HRH1, HRH2 | CALCA 37/4885EGLN1 463/4885DYRK1A 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.